Bispecific and multi-specific antibodies represent an emerging class of therapeutics. Unlike traditional antibodies, these are capable of binding to multiple distinct antigens simultaneously and may offer certain benefits such as improved response rates. Compugen licensed to AstraZeneca rights for the development of bispecific and multi-specific immuno-oncology antibody products derived from COM902 (anti-TIGIT antibody).
Study to Assess the Safety and Efficacy of AZD2936 in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (ARTEMIDE-01)
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung04)
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN)
The Phase 1 study sponsored and conducted by Bayer evaluating the safety and tolerability of BAPOTULIMAB in patients with advanced solid tumors is active and not recruiting.